Autor segons l'article: Moreno-Vedia, Juan; Girona, Josefa; Ibarretxe, Daiana; Masana, Lluis; Rodriguez-Calvo, Ricardo;
Departament: Medicina i Cirurgia Ciències Mèdiques Bàsiques
Autor/s de la URV: Girona Tell, Josefa / Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Moreno Vedia, Juan / Rodríguez Calvo, Ricardo
Paraules clau: Recent insights Nonalcoholic steatohepatitis Mash Mafld Liver steatosis Insulin-resistance Induced hepatic steatosis Hormone-sensitive lipase Gene-expression Fabp4 Endoplasmic-reticulum stress De-novo lipogenesis Adipose-tissue Adipokines Activated receptor-gamma
Resum: Metabolic-associated fatty liver disease (MAFLD), the main cause of chronic liver disease worldwide, is a progressive disease ranging from fatty liver to steatohepatitis (metabolic-associated steatohepatitis; MASH). Nevertheless, it remains underdiagnosed due to the lack of effective non-invasive methods for its diagnosis and staging. Although MAFLD has been found in lean individuals, it is closely associated with obesity-related conditions. Adipose tissue is the main source of liver triglycerides and adipocytes act as endocrine organs releasing a large number of adipokines and pro-inflammatory mediators involved in MAFLD progression into bloodstream. Among the adipocyte-derived molecules, fatty acid binding protein 4 (FABP4) has been recently associated with fatty liver and additional features of advanced stages of MAFLD. Additionally, emerging data from preclinical studies propose FABP4 as a causal actor involved in the disease progression, rather than a mere biomarker for the disease. Therefore, the FABP4 regulation could be considered as a potential therapeutic strategy to MAFLD. Here, we review the current knowledge of FABP4 in MAFLD, as well as its potential role as a therapeutic target for this disease.
Àrees temàtiques: Pharmacology & pharmacy Medicine, research & experimental Medicine (miscellaneous) General biochemistry,genetics and molecular biology Ciencias sociales Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat josefa.girona@urv.cat ricardo.rodriguez@urv.cat josefa.girona@urv.cat luis.masana@urv.cat juan.moreno@estudiants.urv.cat juan.moreno@estudiants.urv.cat
Identificador de l'autor: 0000-0002-6267-8779 0000-0002-6267-8779 0000-0002-0789-4954 0000-0002-2673-3822 0000-0002-2673-3822
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.mdpi.com/2227-9059/10/1/197
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Biomedicines. 10 (1):
Referència de l'ítem segons les normes APA: Moreno-Vedia, Juan; Girona, Josefa; Ibarretxe, Daiana; Masana, Lluis; Rodriguez-Calvo, Ricardo; (2022). Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. Biomedicines, 10(1), -. DOI: 10.3390/biomedicines10010197
DOI de l'article: 10.3390/biomedicines10010197
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2022
Tipus de publicació: Journal Publications